Precision BioSciences (DTIL) Short-Term Debt to Capital

Precision BioSciences, Inc. - graphic logo of issuer DTIL

Precision BioSciences is developing the gene therapy sector through alliances with global pharma behemoths. Current price action reflects the asset's status, where the indicator stands at 0.10. Precision BioSciences has created the unique ARCUS tool for high-precision correction of genetic defects without off-target mutations. The business currently relies exclusively on external financing and grants, as commercial products have not yet been brought to market.

DTIL Precision BioSciences Current Liabilities to Equity (07/04/2022 - 10/28/2026)

Analytical breakdowns for Precision BioSciences

- price and consensus price forecast:
Price Chart Precision BioSciences, Inc.|DTIL - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Precision BioSciences Inc.|DTIL - Enterprise Value
- book capitalization data:
Net Assets per Single Share Precision BioSciences|DTIL - Net Asset Value|Market Value to Book Value Ratio precisionbiosciences.com|DTIL - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Precision BioSciences|DTIL - Long-Term Liabilities to Capital|Short-Term Debt to Capital Precision BioSciences|DTIL - Company Total Debt|Debts to Book Capitalization Precision BioSciences Inc.|DTIL - Long-Term Debt Volume|Company Short-Term Debt Precision BioSciences
Comprehensive company analysis:Precision BioSciences, Inc., DTIL
Manufactured products of Precision BioSciences Inc.

This indicator assesses financial stability by comparing liabilities with a maturity of up to one year against total equity to determine liquidity risks. By analyzing the current short-term debt to equity value on the GURU.Markets platform, an investor can see the extent of Precision BioSciences (DTIL) dependence on rapid refinancing, which is critical when scaling the ARCUS platform in the field of gene editing and oncology therapy.

Competing companies

Short-Term Debt to Equity Tempus AI TEM|Short-Term Debt to Capital Ratio Qiagen Corp (QGEN)|Short-Term Debt to Capital IONS (Ionis Pharmaceuticals)|repligen.com - Short-Term Debt to Capital|Short-Term Debt to Equity Avidity Biosciences, Inc.|CRSP: Current Liabilities to Equity|Short-Term Debt to Equity Sema4 WGS|Ultragenyx Corp (RARE) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital BEAM (Beam Therapeutics Inc.)|Current Liabilities to Capital sarepta.com|Short-Term Debt to Capital TWST (Twist Bioscience, Inc.)|Short-Term Debt to Equity Ratio 10x Genomics Inc (TXG)|Short-Term Debt to Capital NTLA|Stoke Corp - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity BLFS (BioLife Solutions, Inc.)|WVE - Short-Term Debt to Capital Coefficient|Maze Therapeutics - Short-Term Debt to Capital|SION (Sionna Therapeutics, Inc.) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity PRME (Prime Medicine Corp)|Current Liabilities to Capital TSHA|Short-Term Debt to Equity uniQure N.V. QURE|Short-Term Debt to Capital Ratio meiragtx.com MGTX|Short-Term Debt to Equity Ratio REGENXBIO|Ratio of Short-Term Indebtedness to Capital Solid Biosciences Inc SLDB|OCGN - Short-Term Debt to Capital|PACB - Short-Term Debt to Equity|Benitec Biopharma Inc. - Short-Term Debt to Capital|DSGN (designtx.com) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity RCKT (Rocket Pharmaceuticals, Inc.)|Current Liabilities to Capital FDMT|LXEO (Lexeo Therapeutics) - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient korrobio.com (KRRO)|Editas Medicine, Inc. - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio silence-therapeutics.com SLN|Short-Term Debt to Capital PRQR (ProQR Therapeutics NV)|CDXS - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital SGMO|NAUT (Nautilus Bio) - Current Liabilities to Capital|Short-Term Debt to Equity Metagenomi, Inc. (MGX)|Short-Term Debt to Capital Ratio Generation Bio Corp|Short-Term Debt to Capital BOLD (Boundless Bio)|Short-Term Debt to Equity Ratio exicuretx.com (XCUR)|IMNN: Short-Term Debt to Capital|Phio Pharmaceuticals Corp - Current Liabilities to Capital|Short-Term Debt to Equity MBIO (Mustang Bio Corp)|RNAZ - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital bionanogenomics.com|Short-Term Debt to Capital Ratio Applied DNA Sciences Inc|Bluebird Bio (BLUE) - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ImmunoPrecise|OMGA (Omega Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient OMIC (singulargenomics.com)|Short-Term Debt to Equity Regulus Therapeutics Inc. RGLS|Short-Term Debt to Equity Syros Pharmaceuticals Inc. SYRS|Codex DNA (TBIO) - Short-Term Debt to Capital|TCON: Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Unity Biotechnology